Comparative Pharmacology
Head-to-head clinical analysis: DEXASPORIN versus NYSTATIN AND TRIAMCINOLONE ACETONIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXASPORIN versus NYSTATIN AND TRIAMCINOLONE ACETONIDE.
DEXASPORIN vs NYSTATIN AND TRIAMCINOLONE ACETONIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexasporin is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory mediators such as prostaglandins and leukotrienes.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that cause leakage of intracellular contents and cell death. Triamcinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, immune response, and vasodilation.
1 to 2 mg/kg intramuscular or intravenous every 8 hours.
Apply thin layer to affected area twice daily for 2-4 weeks. Topical only.
None Documented
None Documented
3-4 hours (prolonged to 10-15 hours in renal impairment; monitor CrCl <30 mL/min)
Nystatin: not systemically absorbed; terminal half-life not applicable. Triamcinolone acetonide: after intramuscular injection, terminal half-life is approximately 2-5 hours; after topical application, minimal systemic absorption precludes meaningful half-life determination.
Renal excretion (80-90% unchanged), biliary/fecal (10-20%)
Nystatin: primarily excreted unchanged in feces via bile (>90%); negligible renal excretion (<1%). Triamcinolone acetonide: primarily hepatically metabolized; conjugated metabolites excreted renally (70%) and via bile (20% fecal). Systemic absorption of triamcinolone acetonide after topical application is minimal (<1%).
Category C
Category D/X
Corticosteroid/Antibiotic Combination
Corticosteroid